$5.75
-1.26-18.05%
Últ. Act.: Oct 23, 3:57 PM
Phathom Pharmaceuticals (PHAT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Phathom Pharmaceuticals (PHAT) publicó su última previsión de julio 30, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $310M - $325M para el período.
En comparación con la previsión anterior, Phathom Pharmaceuticals reducido redujo su previsión de ingresos desde un rango anterior de $320M - $345M.
Phathom Pharmaceuticals ha emitido 7 actualizaciones de orientación entre el agosto 6, 2025 y el julio 30, 2026. During this period, the company raised its outlook 3 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.11 | $-0.21 | $-0.19 | $-0.41 |
| Actual | $0.00 | $-0.18 | $-0.08 | $-0.15 |
| Surprise | +100.0% | +14.3% | +57.9% | +63.4% |
| Revenue | ||||
| Estimate | $73.6M | $56.8M | $57.4M | $47.9M |
| Actual | $74.3M | $58.3M | $57.6M | $49.5M |
| Surprise | +1.01% | +2.66% | +0.26% | +3.41% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $0.02 | $0.10 |
| Revenue | ||
| Consensus | $85.2M | $98.4M |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $0 | $-0.11 | 100.0 % |
| Q1 | Apr 30, 2026 | $-0.18 | $-0.21 | 14.3 % |
| Q4 | Feb 26, 2026 | $-0.08 | $-0.19 | 57.9 % |
| Q3 | Oct 30, 2025 | $-0.15 | $-0.41 | 63.4 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $74.30M | $73.55M | 1.01 % |
| Q1 | Apr 30, 2026 | $58.30M | $56.79M | 2.66 % |
| Q4 | Feb 26, 2026 | $57.58M | $57.43M | 0.26 % |
| Q3 | Oct 30, 2025 | $49.50M | $47.87M | 3.41 % |